Literature DB >> 18835005

A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.

Grégoire Martin1, Yide Sun, Bernadette Heyd, Olivier Combes, Jeffrey B Ulmer, Anne Descours, Susan W Barnett, Indresh K Srivastava, Loïc Martin.   

Abstract

To counteract the problems associated with the purification of HIV envelope, we developed a new purification method exploiting the high affinity of a peptide mimicking CD4 towards the viral glycoprotein. This miniCD4 was used as a ligand in affinity chromatography and allowed the separation in one step of HIV envelope monomer from cell supernatant and the capture of pre-purified trimer. This simple and robust method of purification yielded to active and intact HIV envelopes as proved by the binding of CCR5 HIV co-receptor, CD4 and a panel of well-characterized monoclonal antibodies. The immunogenicity of miniCD4-purified HIV envelope was further assessed in rats. The analysis of the humoral response indicated that elicited antibodies were able to recognize a broad range of HIV envelopes. Finally, this method based on a chemically synthesized peptide may represent a convenient and versatile tool for protein purification compatible far scale-up in both academic and pharmaceutical researches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835005      PMCID: PMC2645002          DOI: 10.1016/j.virol.2008.08.039

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  52 in total

Review 1.  Candidate AIDS vaccines.

Authors:  B S Graham; P F Wright
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

2.  Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies.

Authors:  D H Jones; B W McBride; M A Roff; G H Farrar
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

3.  HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.

Authors:  T Wrin; J H Nunberg
Journal:  AIDS       Date:  1994-11       Impact factor: 4.177

4.  Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.

Authors:  C C Broder; P L Earl; D Long; S T Abedon; B Moss; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

5.  Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen.

Authors:  T C VanCott; S C Veit; V Kalyanaraman; P Earl; D L Birx
Journal:  J Immunol Methods       Date:  1995-06-14       Impact factor: 2.303

6.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Authors:  J R Mascola; S W Snyder; O S Weislow; S M Belay; R B Belshe; D H Schwartz; M L Clements; R Dolin; B S Graham; G J Gorse; M C Keefer; M J McElrath; M C Walker; K F Wagner; J G McNeil; F E McCutchan; D S Burke
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

7.  Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

Authors:  M Girard; B Meignier; F Barré-Sinoussi; M P Kieny; T Matthews; E Muchmore; P L Nara; Q Wei; L Rimsky; K Weinhold
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

Authors:  P W Parren; H J Ditzel; R J Gulizia; J M Binley; C F Barbas; D R Burton; D E Mosier
Journal:  AIDS       Date:  1995-06       Impact factor: 4.177

9.  Human immunodeficiency virus-1 glycoproteins gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway.

Authors:  D Cefai; P Debre; M Kaczorek; T Idziorek; B Autran; G Bismuth
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

10.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  6 in total

1.  Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120.

Authors:  Julie Matz; Pascal Kessler; Jérôme Bouchet; Olivier Combes; Oscar Henrique Pereira Ramos; Francis Barin; Daniel Baty; Loïc Martin; Serge Benichou; Patrick Chames
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

2.  MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.

Authors:  Katrijn Grupping; Philippe Selhorst; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Pascal Kessler; Guido Vanham; Loïc Martin; Kevin K Ariën
Journal:  Retrovirology       Date:  2012-05-02       Impact factor: 4.602

3.  Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Klara Sirokman; Avishek Nandi; Karin Hartog; Ying Lian; Anthony R Geonnotti; David Montefiori; Michael Franti; Grégoire Martin; Andrea Carfi; Pascal Kessler; Loïc Martin; Indresh K Srivastava; Susan W Barnett
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

4.  Functional Mimetics of the HIV-1 CCR5 Co-Receptor Displayed on the Surface of Magnetic Liposomes.

Authors:  Alona Kuzmina; Karin Vaknin; Garik Gdalevsky; Maria Vyazmensky; Robert S Marks; Ran Taube; Stanislav Engel
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

5.  M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures.

Authors:  Giuseppina Musumeci; Isabella Bon; David Lembo; Valeria Cagno; Maria Carla Re; Caterina Signoretto; Erica Diani; Lucia Lopalco; Claudia Pastori; Loïc Martin; Gilles Ponchel; Davide Gibellini; Kawthar Bouchemal
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

6.  Hydroponic Treatment of Nicotiana benthamiana with Kifunensine Modifies the N-glycans of Recombinant Glycoprotein Antigens to Predominantly Man9 High-Mannose Type upon Transient Overexpression.

Authors:  Sugata Roychowdhury; Young J Oh; Hiroyuki Kajiura; Krystal T Hamorsky; Kazuhito Fujiyama; Nobuyuki Matoba
Journal:  Front Plant Sci       Date:  2018-01-30       Impact factor: 5.753

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.